Picture of Takeda Pharmaceutical Co logo

4502 Takeda Pharmaceutical Co Cashflow Statement

0.000.00%
jp flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

Annual cashflow statement for Takeda Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

2021
March 31st
2022
March 31st
2023
March 31st
2024
March 31st
2025
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:YuhoYuhoYuhoYuhoTanshin
Standards:
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line376,171230,166317,038144,197108,143
Depreciation
Non-Cash Items12,308252,109327,626182,842452,700
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital62,78157,679-331,908-338,697-265,057
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities1,010,9311,123,105977,156716,3441,057,182
Capital Expenditures-236,468-186,037-633,689-480,730-347,841
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items629,998-12,08826,58716,868-19,219
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities393,530-198,125-607,102-463,862-367,060
Financing Cash Flow Items-142,352-108,592-117,732-126,478-129,633
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-1,088,354-1,070,265-709,148-354,416-751,425
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash328,608-116,527-316,165-75,730-72,688